Participated · Equity · Aug 2026

Singular Photonics is an Edinburgh-based fabless semiconductor spinout from the University of Edinburgh built on research led by Professor Robert Henderson. The company develops image sensors based on single-photon avalanche diode (SPAD) technology that can detect and precisely time individual photons, enabling high-sensitivity and precise-timing imaging. Singular Photonics combines SPAD detectors with on-chip computation so data can be processed at the point of detection, reducing external data transfer and enabling real-time analysis. It currently offers two commercially available product families, Andarta and Sirona. The company's target application areas include machine vision, industrial automation, physical AI, scientific research and medical imaging. Recent financing of $2.15M is intended to expand engineering capacity and accelerate development and product introductions.

Participated · Seed · Dec 2025

HotHouse Therapeutics, based in Norwich, Norfolk, has developed an AI-driven plant bioengineering system capable of designing and growing new chemistry within days. The platform combines pathway-prediction algorithms with the vast enzymatic diversity of the plant kingdom and can currently generate over 20 million novel molecules. Its vertical-farm-ready production process is carbon positive, offering a sustainable and affordable alternative to extractive or resource-heavy chemical synthesis. The company’s initial commercial focus is on producing next-generation vaccine adjuvants, but management also plans to launch traditional drug-discovery programs and progress selected assets into clinical development. By coupling rapid molecule generation with scalable cultivation, the company aims to shorten R&D timelines and lower production costs for biologically active compounds. The recent funding marks the company’s first institutional capital, positioning it to expand operations and intensify R&D efforts around its discovery pipeline.

Participated · Equity · Feb 2025

Monument Therapeutics is developing MT1988, a novel fixed‑dose combination drug aimed at treating cognitive impairment associated with schizophrenia (CIAS). The company pairs the drug with a computer‑based digital biomarker that measures latent inhibition to stratify patients by attentional filtering and predict likely responders. MT1988 has shown substantial cognitive improvement in preclinical studies and combines two well‑characterised small molecules acting on nicotinic receptors, formulated to enhance cognition while mitigating common side effects. Monument is conducting a Phase 1 safety study in healthy volunteers and expects results by the end of next month (also noted as expected in Q2 2025); if successful it plans Phase 2 trials in early‑stage schizophrenia patients later this year. The drug is intended to be used alongside existing antipsychotic medications as a complementary therapy. The company recently raised funding to support progression of MT1988 through further clinical development. Monument Therapeutics is a Manchester, UK-based precision neuroscience company led by CEO Dr Jenny Barnett. The company leverages a novel drug development strategy that uses digital assessments of cognition to match patients with pharmaceutical treatments. Its lead asset, MT1988, targets the cognitive symptoms of schizophrenia. Monument plans to use newly raised funds to support the clinical development of MT1988. The company announced a £1M equity investment from the Forster Foundation alongside two board appointments—Dr Randeep Grewal as Chair and David Ford as an Investor Director. The financing is intended to advance MT1988 toward clinical milestones and further the company’s precision‑neuroscience approach. Monument Therapeutics is a precision neuroscience company spun out of Cambridge Cognition in 2021 that uses proprietary digital biomarkers and digital cognitive assessments to stratify patients for CNS drug development. The company focuses on matching patients with appropriately targeted compounds to reduce heterogeneity in trials. Its pipeline includes programmes for cognitive impairment in schizophrenia and for neuroinflammation; the lead candidate, MT1988, is a novel fixed‑dose combination that showed substantial cognitive improvement in preclinical studies. Monument has completed a £1.0m fundraise and announced a further £0.5m grant to enable clinical development of MT1988, with first clinical trials expected to begin in the coming weeks. If those trials are successful, a Phase 2 clinical trial is expected to begin in early 2025. Cambridge Cognition retains a significant shareholding in Monument, which was reduced from 28% to 25% after the round. Monument Therapeutics is a spin-out from Cambridge Cognition that develops digital biomarkers to stratify patients in neuroscience drug development. It uses proprietary cognitive assessments licensed from Cambridge Cognition, including CANTABTM, to identify patient subgroups with homogeneous neurobiology. The company combines these digital stratification tools with repurposed drugs that have favourable safety profiles to de‑risk development. Its lead programmes target cognitive impairment in schizophrenia and post-operative cognitive dysfunction (POCD). Monument plans to commercialise its digital biomarkers across multiple neuroscience indications to support R&D and therapeutic development. The company relocated to Alderley Park, Cheshire and appointed Jenny Barnett as CEO; Cambridge Cognition has retained a minority shareholding.

Participated · Seed · Dec 2023

MitoRx Therapeutics operates as a platform biotech focused on translating mitochondrial biology into novel therapeutics for obesity and broader metabolic disorders. Its lead candidates are innovative small-molecule metabolic modulators designed to induce weight loss without compromising muscle integrity, a key differentiator in the crowded obesity-drug landscape. The company is currently at the preclinical stage and is building a pipeline around these modulators. With its recent pre-seed capital raise of roughly $7.3 million, MitoRx will accelerate preclinical validation studies, prepare for future regulatory submissions, and expand both its scientific team and laboratory infrastructure. Management plans to deploy the funds toward advancing its lead programs through early development milestones. Although still pre-revenue, the influx of capital signifies investor confidence in the company’s scientific approach and commercial potential. MitoRx’s near-term objectives include scaling its research footprint and progressing toward clinical readiness. Over the longer term, it aims to deliver differentiated treatments that improve metabolic health and preserve muscle mass in millions of patients.

Participated · Equity · Dec 2023

Spotta develops proprietary artificial intelligence combined with ultra-low-power Internet of Things monitoring devices to provide real-time pest detection and actionable insights. The company holds patented technology and has received multiple awards for its work. Spotta’s platform is already deployed commercially across more than 20 countries. Leadership positions the business as an early leader in pest-management technology, supported by an experienced management team. The recent £3.4 million funding round will fund continued product development and commercial expansion. The company is based in Cambridge.